BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 27194433)

  • 1. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
    Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
    J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Molecular Mechanisms of the Pathogenesis of Parkinson's Disease in a Mouse Neurotoxic Model of the Earliest Preclinical Stage of This Disease.
    Kolacheva A; Pavlova E; Bannikova A; Bogdanov V; Ugrumov M
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of early diagnosis of Parkinson's disease on animal models based on the intranasal administration of α-methyl-p-tyrosine methyl ester in a gel system.
    Kim A; Pavlova E; Kolacheva A; Bogdanov V; Dilmukhametova L; Blokhin V; Valuev L; Valuev I; Gorshkova M; Ugrumov M
    Biomed Pharmacother; 2022 Jun; 150():112944. PubMed ID: 35405394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A; Mura A; Hengerer B; Feldon J; Ferger B
    Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
    Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS
    Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.
    Ugrumov MV; Khaindrava VG; Kozina EA; Kucheryanu VG; Bocharov EV; Kryzhanovsky GN; Kudrin VS; Narkevich VB; Klodt PM; Rayevsky KS; Pronina TS
    Neuroscience; 2011 May; 181():175-88. PubMed ID: 21382448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
    Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
    Xiao-Feng L; Wen-Ting Z; Yuan-Yuan X; Chong-Fa L; Lu Z; Jin-Jun R; Wen-Ya W
    Eur J Pharmacol; 2016 Nov; 791():348-354. PubMed ID: 27614126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
    Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
    J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice.
    Khakimova GR; Kozina EA; Buneeva OA; Aksenova LN; Medvedev AE; Ugryumov MV
    Bull Exp Biol Med; 2015 Aug; 159(4):456-8. PubMed ID: 26388575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.